Follow
Jana Jakubikova
Jana Jakubikova
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane-and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells
J Jakubíková, J Sedlák, R Mithen, Y Bao
Biochemical pharmacology 69 (11), 1543-1552, 2005
2122005
Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice
L Kucerova, M Matuskova, A Pastorakova, S Tyciakova, J Jakubikova, ...
The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2008
2082008
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
J Jakubikova, S Adamia, M Kost-Alimova, S Klippel, D Cervi, JF Daley, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4409-4419, 2011
1822011
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
J Minami, R Suzuki, R Mazitschek, G Gorgun, B Ghosh, D Cirstea, Y Hu, ...
Leukemia 28 (3), 680-689, 2014
1632014
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition
M Cea, A Cagnetta, M Fulciniti, YT Tai, T Hideshima, D Chauhan, ...
Blood, The Journal of the American Society of Hematology 120 (17), 3519-3529, 2012
1572012
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ...
Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012
1542012
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
DW McMillin, M Ooi, J Delmore, J Negri, P Hayden, N Mitsiades, ...
Cancer research 69 (14), 5835-5842, 2009
1542009
Isothiocyanates induce cell cycle arrest, apoptosis and mitochondrial potential depolarization in HL-60 and multidrug-resistant cell lines
J Jakubikova, Y Bao, J Sedlák
Anticancer Research 25 (5), 3375-3386, 2005
1452005
Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells
V Švehlíková, S Wang, J Jakubíková, G Williamson, R Mithen, Y Bao
Carcinogenesis 25 (9), 1629-1637, 2004
1172004
Garlic-derived organosulfides induce cytotoxicity, apoptosis, cell cycle arrest and oxidative stress in human colon carcinoma cell lines.
J Jakubikova, J Sedlak
Neoplasma 53 (3), 191-199, 2006
1032006
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma
J Jakubikova, D Cervi, M Ooi, K Kim, S Nahar, S Klippel, D Cholujova, ...
Haematologica 96 (8), 1170, 2011
932011
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
R O’Connor, MG Ooi, J Meiller, J Jakubikova, S Klippel, J Delmore, ...
Cancer chemotherapy and pharmacology 71, 1357-1368, 2013
892013
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance
SJ de Haart, NWCJ van de Donk, MC Minnema, JH Huang, ...
Clinical cancer research 19 (20), 5591-5601, 2013
782013
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
S Kikuchi, R Suzuki, H Ohguchi, Y Yoshida, D Lu, F Cottini, J Jakubikova, ...
Leukemia 29 (9), 1918-1927, 2015
762015
MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients
D Cholujova, J Jakubikova, B Czako, M Martisova, L Hunakova, J Duraj, ...
Cancer Immunology, Immunotherapy 62, 437-445, 2013
732013
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications
J Jakubikova, D Cholujova, T Hideshima, P Gronesova, A Soltysova, ...
Oncotarget 7 (47), 77326, 2016
722016
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
T Hideshima, F Cottini, H Ohguchi, J Jakubikova, G Gorgun, N Mimura, ...
Blood cancer journal 5 (5), e312-e312, 2015
722015
Comparative study of four fluorescent probes for evaluation of natural killer cell cytotoxicity assays
D Cholujová, J Jakubíková, M Kubeš, B Arendacká, M Sapák, R Ihnatko, ...
Immunobiology 213 (8), 629-640, 2008
722008
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition
N Mimura, T Hideshima, T Shimomura, R Suzuki, H Ohguchi, O Rizq, ...
Cancer research 74 (16), 4458-4469, 2014
712014
Cytotoxic and DNA‐Damaging Effects of Diterpenoid Quinones from the Roots of Salvia officinalis L. on Colonic and Hepatic Human Cells Cultured in vitro
D Slameňová, I Mašterová, J Lábaj, E Horváthová, P Kubala, ...
Basic & clinical pharmacology & toxicology 94 (6), 282-290, 2004
702004
The system can't perform the operation now. Try again later.
Articles 1–20